ImmunityBio's (IBRX) "Buy" Rating Reaffirmed at D. Boral Capital

Key Points

• D. Boral Capital reaffirmed a "Buy" rating on ImmunityBio with a $23 price target, implying about a 180.7% upside from the prior close.
• Analysts overall rate the stock a "Moderate Buy" (1 Strong Buy, 5 Buy, 1 Sell) with a $14.40 consensus target; IBRX traded near $8.20 with a market cap of $8.43 billion and recent 50/200‑day moving averages of $8.02/$4.78.
• Legal and regulatory risk is elevated—multiple class‑action filings and an FDA warning letter over alleged misleading efficacy claims tied to the company’s executive chairman are cited as major investor concerns.

ImmunityBio (NASDAQ:IBRX - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $23.00 price objective on the stock. D. Boral Capital's price target would indicate a potential upside of 180.66% from the stock's previous close.

Other equities analysts have also issued research reports about the stock. The Goldman Sachs Group reaffirmed a "buy" rating on shares of ImmunityBio in a research report on Monday, February 23rd. BTIG Research started coverage on ImmunityBio in a report on Thursday, March 12th. They set a "buy" rating and a $13.00 price target on the stock. Piper Sandler reiterated an "overweight" rating and set a $12.00 price target (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. HC Wainwright increased their price target on ImmunityBio from $10.00 to $15.00 and gave the company a "buy" rating in a report on Monday, February 23rd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of ImmunityBio in a report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $14.40.

ImmunityBio Price Performance

IBRX traded down $0.01 during midday trading on Tuesday, hitting $8.20. 6,779,241 shares of the company's stock traded hands, compared to its average volume of 34,624,230. The company has a market cap of $8.43 billion, a PE ratio of -21.57 and a beta of 0.13. The stock's fifty day simple moving average is $8.02 and its 200-day simple moving average is $4.78. ImmunityBio has a one year low of $1.83 and a one year high of $12.43.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last issued its quarterly earnings data on Monday, February 23rd. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. The business had revenue of $38.29 million for the quarter. On average, research analysts expect that ImmunityBio will post -0.31 EPS for the current year.

Insider Activity

In other ImmunityBio news, Director Christobel Selecky sold 25,000 shares of the business's stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Barry J. Simon sold 75,000 shares of the company's stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total value of $900,750.00. Following the completion of the sale, the director directly owned 2,850,821 shares of the company's stock, valued at approximately $34,238,360.21. This trade represents a 2.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 275,000 shares of company stock valued at $2,934,500 over the last three months. Company insiders own 69.48% of the company's stock.

Institutional Trading of ImmunityBio

A number of large investors have recently bought and sold shares of the business. Mariner LLC increased its stake in ImmunityBio by 10.5% during the 4th quarter. Mariner LLC now owns 17,814 shares of the company's stock worth $35,000 after purchasing an additional 1,689 shares in the last quarter. Sanctuary Advisors LLC increased its stake in ImmunityBio by 6.9% during the 4th quarter. Sanctuary Advisors LLC now owns 29,547 shares of the company's stock worth $59,000 after purchasing an additional 1,918 shares in the last quarter. Sequoia Financial Advisors LLC increased its stake in ImmunityBio by 8.6% during the 4th quarter. Sequoia Financial Advisors LLC now owns 28,783 shares of the company's stock worth $57,000 after purchasing an additional 2,271 shares in the last quarter. Mutual Advisors LLC increased its stake in ImmunityBio by 9.0% during the 4th quarter. Mutual Advisors LLC now owns 30,200 shares of the company's stock worth $60,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Commonwealth Equity Services LLC increased its stake in ImmunityBio by 4.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 75,776 shares of the company's stock worth $150,000 after purchasing an additional 3,280 shares in the last quarter. 8.58% of the stock is owned by institutional investors.

ImmunityBio News Summary

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio announced commercial availability of ANKTIVA® in Saudi Arabia for approved bladder and lung cancer indications — initial patients identified, expanding the drug’s market footprint in MENA and supporting near‑term revenue potential. Business Wire: ANKTIVA now available in Saudi Arabia
• Positive Sentiment: Media coverage highlights bullish commentary from the company founder about a possible Anktiva breast‑cancer immune signal, which has helped support recent buying interest and has been cited as a reason for a short‑term rally in the stock. MSN: Founder flags bull case for Anktiva
• Negative Sentiment: Hagens Berman and other firms point to an FDA warning letter about misleading efficacy claims by the company’s executive chairman — this regulatory concern is central to the class‑action allegations and is a major catalyst for investor worry. GlobeNewswire: Hagens Berman investor deadline / FDA warning letter
• Negative Sentiment: Schall Law Firm reminds investors of a pending securities‑fraud lawsuit covering purchases between Jan. 19–Mar. 24, 2026 and solicits lead plaintiff interest — another legal notice that increases litigation risk and potential distraction for management. GlobeNewswire: Schall Law Firm notice
• Negative Sentiment: Multiple national plaintiff firms (Faruqi & Faruqi, Bernstein Liebhard, Rosen, Robbins, Levi & Korsinsky, Kessler Topaz, Lowey Dannenberg, etc.) have filed or announced investigations and are advertising the May 26, 2026 lead‑plaintiff deadline — the volume of suits/solicitations amplifies legal and reputational risk. Representative notices: Bernstein Liebhard. Newsfile: Bernstein Liebhard deadline alert

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.